Anti-Tumor Activity Assessment in Patients with Advanced Gynecological CancersStatus: open
17-071 - CL-PTL-126 A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients with Advanced Gynecological Cancers
Treatment for Gynecological Cancer
This is a crossover study of Vigil, Atezolizumab and their combination in patients who have tumor harvested at surgery and successful manufacturing of Vigil but are ineligible for CL-PTL-119 (the VITAL study) or previously randomized to placebo. IRB Number 17-071
SponsorsThis trial is sponsored by Gradalis.
Interested in Clinical Trial?
Providers Associated With This Trial
- Rodney P. Rocconi, M.D., F.A.C.O.G.Gynecologic OncologistInterim Director of Mitchell Cancer Institute; Chief of Gynecologic Oncology Service; Associate Director for Clinical Research, Abraham A. Mitchell Clinical Cancer Research Scholar; Professor of Interdisciplinary Clinical Oncology
- Jennifer M. Scalici, M.D.Gynecologic OncologistAssociate Professor of Interdisciplinary Clinical Oncology